128 related articles for article (PubMed ID: 34902746)
1. Genome-wide CRISPR/Cas9 knockout screening uncovers ZNF319 as a novel tumor suppressor critical for breast cancer metastasis.
Wang L; Zhou L; Li M; Zhao J; Liu Y; Chen Y; Qin X; Wang S; Chen H; Piao Y; Xiang R; Li J; Shi Y
Biochem Biophys Res Commun; 2022 Jan; 589():107-115. PubMed ID: 34902746
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
[TBL] [Abstract][Full Text] [Related]
3. Tumor-suppressor function of Beclin 1 in breast cancer cells requires E-cadherin.
Wijshake T; Zou Z; Chen B; Zhong L; Xiao G; Xie Y; Doench JG; Bennett L; Levine B
Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33495338
[TBL] [Abstract][Full Text] [Related]
4. Targeting RLIP with CRISPR/Cas9 controls tumor growth.
Singhal J; Chikara S; Horne D; Awasthi S; Salgia R; Singhal SS
Carcinogenesis; 2021 Feb; 42(1):48-57. PubMed ID: 32426802
[TBL] [Abstract][Full Text] [Related]
5. The tumor suppressor Zinc finger protein 471 suppresses breast cancer growth and metastasis through inhibiting AKT and Wnt/β-catenin signaling.
Tao C; Luo J; Tang J; Zhou D; Feng S; Qiu Z; Putti TC; Xiang T; Tao Q; Li L; Ren G
Clin Epigenetics; 2020 Nov; 12(1):173. PubMed ID: 33203470
[TBL] [Abstract][Full Text] [Related]
6. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
[TBL] [Abstract][Full Text] [Related]
7. Genome editing approaches with CRISPR/Cas9: the association of NOX4 expression in breast cancer patients and effectiveness evaluation of different strategies of CRISPR/Cas9 to knockout Nox4 in cancer cells.
Javadi M; Sazegar H; Doosti A
BMC Cancer; 2023 Nov; 23(1):1155. PubMed ID: 38012557
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis.
Zhang J; Li Y; Liu H; Zhang J; Wang J; Xia J; Zhang Y; Yu X; Ma J; Huang M; Wang J; Wang L; Li Q; Cui R; Yang W; Xu Y; Feng W
J Exp Clin Cancer Res; 2022 Jan; 41(1):24. PubMed ID: 35033172
[TBL] [Abstract][Full Text] [Related]
9. C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes.
Lu J; Wen M; Huang Y; He X; Wang Y; Wu Q; Li Z; Castellanos-Martin A; Abad M; Cruz-Hernandez JJ; Rodriguez CA; Pérez-Losada J; Mao JH; Wei G
Epigenetics; 2013 Jun; 8(6):571-83. PubMed ID: 23770814
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9 mediated knocking out of OPN gene enhances radiosensitivity in MDA-MB-231 breast cancer cell line.
Ghanbarnasab Behbahani R; Danyaei A; Teimoori A; Tahmasbi MJ; Neisi N
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4117-4130. PubMed ID: 36042045
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.
Tordjman J; Majumder M; Amiri M; Hasan A; Hess D; Lala PK
BMC Cancer; 2019 Jun; 19(1):561. PubMed ID: 31185986
[TBL] [Abstract][Full Text] [Related]
12. Protocadherin 17 functions as a tumor suppressor suppressing Wnt/β-catenin signaling and cell metastasis and is frequently methylated in breast cancer.
Yin X; Xiang T; Mu J; Mao H; Li L; Huang X; Li C; Feng Y; Luo X; Wei Y; Peng W; Ren G; Tao Q
Oncotarget; 2016 Aug; 7(32):51720-51732. PubMed ID: 27351130
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 knock-out via CRISPR/Cas9 altered Casp-9, Bax, CCND1, CDK4, and fibronectin expressions in LNCaP cells.
Albayrak G; Konac E; Ugras Dikmen A; Bilen CY
Exp Biol Med (Maywood); 2018 Aug; 243(12):990-994. PubMed ID: 30043639
[TBL] [Abstract][Full Text] [Related]
14. Comparative use of CRISPR and RNAi to modulate integrin α3β1 in triple negative breast cancer cells reveals that some pro-invasive/pro-metastatic α3β1 functions are independent of global regulation of the transcriptome.
Kenney J; Ndoye A; Lamar JM; DiPersio CM
PLoS One; 2021; 16(7):e0254714. PubMed ID: 34270616
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide CRISPR knockout screening identified G protein pathway suppressor 2 as a novel tumor suppressor for uveal melanoma metastasis.
Shi S; Chen H; Wang H; Wan J; Shi Y; Li J; Wang S; Shi J; Lv J; Wu T; Wang L; Sun F
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3349-3360. PubMed ID: 35941228
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis.
Chen S; Sanjana NE; Zheng K; Shalem O; Lee K; Shi X; Scott DA; Song J; Pan JQ; Weissleder R; Lee H; Zhang F; Sharp PA
Cell; 2015 Mar; 160(6):1246-60. PubMed ID: 25748654
[TBL] [Abstract][Full Text] [Related]
17. Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress.
Hegge B; Sjøttem E; Mikkola I
BMC Cancer; 2018 May; 18(1):496. PubMed ID: 29716531
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9-mediated knockout of HO-1 decreased the proliferation and migration of T47D cells and increased cisplatin-induced apoptosis: an in vitro study.
Evazi Bakhshi S; Mohammadi Roushandeh A; Habibi Roudkenar M; Shekarchi S; Bahadori MH
Med Oncol; 2022 Aug; 39(11):175. PubMed ID: 35972707
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-3613-3p functions as a tumor suppressor and represents a novel therapeutic target in breast cancer.
Chen C; Pan Y; Bai L; Chen H; Duan Z; Si Q; Zhu R; Chuang TH; Luo Y
Breast Cancer Res; 2021 Jan; 23(1):12. PubMed ID: 33494814
[TBL] [Abstract][Full Text] [Related]
20. CHFR‑mediated epithelial‑to‑mesenchymal transition promotes metastasis in human breast cancer cells.
Jiang G; Fang H; Shang X; Chen X; Cao F
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33880594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
